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Background Clinical response to chemotherapy for ovarian cancer is frequently 
compromised by the development of drug-resistant disease. The underlying molecular 
mechanisms and implications for prescription of routinely prescribed chemotherapy drugs 
are poorly understood.  
Methods We created novel A2780-derived ovarian cancer cell lines resistant to paclitaxel 
and olaparib, following continuous incremental drug selection. MTT assays were used to 
assess chemosensitivity to paclitaxel and olaparib in drug-sensitive and drug-resistant cells ± 
the ABCB1 inhibitors verapamil and elacridar, and cross-resistance to cisplatin, carboplatin, 
doxorubicin, rucaparib, veliparib and AZD2461.  ABCB1 expression was assessed by qRT-PCR, 
copy number, Western blot and immunohistochemical analysis and ABCB1 activity assessed 
by Vybrant™ and P-glycoprotein-Glo™ assays.  
Results Paclitaxel-resistant cells were cross-resistant to olaparib, doxorubicin and rucaparib, 
but not veliparib or AZD2461.  Resistance correlated with increased ABCB1 expression, and 
was reversible following treatment with the ABCB1 inhibitors verapamil and elacridar.  
Active efflux of paclitaxel, olaparib, doxorubicin and rucaparib was confirmed in drug-
resistant cells and in ABCB1-expressing bacterial membranes. 
Conclusion We describe a common ABCB1-mediated mechanism of paclitaxel and olaparib 
resistance in ovarian cancer cells. Optimal choice of PARP inhibitor may therefore limit the 
progression of drug resistant disease, while routine prescription of first-line paclitaxel may 
significantly limit subsequent chemotherapy options in ovarian cancer patients.  
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Ovarian cancer, the most common and most lethal gynaecological malignancy, is commonly 
initially treated with combination chemotherapy, most frequently combining the platinum 
drug carboplatin with the taxane paclitaxel ((SIGN), 2013). While a minority of ovarian 
cancer patients are inherently drug resistant, development of chemotherapy-induced 
adaptive drug resistance is a common treatment-limiting complication in the majority of 
patients – understanding the molecular events which lead to the development of drug-
resistant disease is therefore a clinical priority (Vaughan et al, 2011). Increased 
understanding of causal molecular mechanisms may facilitate biomarker development to 
predict and monitor the onset of drug-resistant disease in individual patients, and inform 
the most rational prescription of alternative second-line chemotherapy, where a variety of 
drugs are currently being evaluated in clinical trials, including the PARP inhibitors olaparib, 
veliparib (ABT-888) and rucaparib (Sonnenblick et al, 2015). 
 
PARP inhibitors (PARPi) are drugs which primarily inhibit PARP1 (poly (ADP-ribose) 
polymerase), an enzyme with a key role in single-strand break DNA repair, and were 
rationally designed to promote selective toxicity through exploitation of synthetic lethality 
resulting from targeting alternative or compensatory DNA repair pathways (Bryant et al, 
2005; Farmer et al, 2005). Individuals inheriting relatively rare mutations (5-10% of breast 
and ovarian cancer patients) in the tumour suppressor genes BRCA1 or BRCA2, proteins 
which play an essential role in homologous recombination (HR)-mediated repair of DNA 
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double strand breaks, have increased risk of developing breast and ovarian cancer, but are 
particularly sensitive to olaparib and similar PARPi drugs (Audeh et al, 2010; Tutt et al, 2010). 
Olaparib has recently been licensed for maintenance treatment of ovarian cancer patients 
following first-line chemotherapy (Oza et al, 2015), while increased understanding of the 
molecular basis of the  “BRCA-like” or “BRCAness” phenotype may lead to future extension 
of current PARPi licensing (Rouleau et al, 2010).  Before PARP inhibitors can be routinely 
prescribed, however, it is clearly important that PARPi-induced resistance mechanisms are 
better understood, and that the potential for treatment-limiting resistance mechanisms 
common both to PARP inhibitors and conventional chemotherapy is evaluated. 
 
The majority of recent studies on PARPi-induced drug resistance mechanisms have focused 
on adaptive changes in the DNA damage response, for example describing restoration of HR 
function following the acquisition of secondary BRCA mutations (Edwards et al, 2008; Sakai 
et al, 2008), HSP-90 mediated stabilisation of mutant BRCA1 (Johnson et al, 2013), RAD51 
up-regulation (Martin et al, 2007), loss of REV7 (Xu et al, 2015) or promotion of alternative 
error-prone non-homologous end joining (NHEJ) DNA repair (Patel et al, 2011). Similarity in 
patient chemosensitivity profiles following treatment with platinum drugs and PARP 
inhibitors and common resistance mechanisms, where in vitro selection in one drug 
promotes cross-resistance to the other have been described (Edwards et al, 2008; Sakai et al, 
2008; Tutt et al, 2010), while BRCA1 revertant mutations have been reported in carboplatin-
resistant ovarian cancer patients (Norquist et al, 2011; Swisher et al, 2008).  
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In contrast, increased expression of the ATP-dependent efflux pump ABCB1 (MDR1) which 
encodes the membrane drug transporter P-glycoprotein, is a well-described resistance 
mechanism for doxorubicin, paclitaxel and related taxane drugs (Fojo et al, 1987; Parekh et 
al, 1997; Shen et al, 1986). Increased ABCB1 copy number resulting from a chromosomal 
amplification event at 7q11.2-21 has been correlated with increased P-glycoprotein 
expression in paclitaxel-resistant cells from various cancers including ovarian cancer (Wang 
et al, 2006), with resulting drug-resistant phenotypes confirmed in ABCB1 over-expression 
and P-glycoprotein inhibitor studies (Lawlor et al, 2014). Intriguingly, recent reports have 
described increased expression of the homologous murine Abcb1a and Abcb1b genes in an 
olaparib resistant mouse breast cancer model (Rottenberg et al, 2008) and in mouse and 
human lymphocytes (Dumitriu et al, 2004). A functional role for murine ATP transporters in 
oral bioavailability and brain accumulation of rucaparib has recently been described 
(Durmus et al, 2015), although the role of ABCB1 in olaparib resistance in ovarian cancer has 
not been investigated. 
 
We now describe the creation of a novel olaparib-resistant A2780-derived ovarian cancer 
cell line (A2780olapR), and highlight an ABCB1-mediated resistance mechanism common to 
paclitaxel, doxorubicin and rucaparib.  Our findings are highly clinically relevant, as our data 
suggests that prescription of specific PARP inhibitors as second-line or maintenance 
treatment may not be appropriate in the majority of ovarian cancer patients where clinical 
response is compromised by paclitaxel-induced drug resistance.  
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The ovarian cancer cell line A2780 was obtained from the European Collection of Cell 
Culture (ECACC, https://www.phe-culturecollections.org.uk/collections/ecacc.aspx). 
Olaparib-resistant (A2780olapR) and paclitaxel-resistant (A2780pacR) cells were created 
following continuous incremental drug selection. MTT cytotoxicity assays (Mosmann, 1983) 
were used as described below to assess olaparib and paclitaxel sensitivity in A2780 cells, 
and to identify initial drug concentrations toxic to approximately 50% of cells (1µM olaparib 
and 3nM paclitaxel, respectively). Drug concentrations were then incrementally increased to 
final concentrations of 20µM (A2780olapR) to mimic typical steady-state plasma 
concentrations in ovarian cancer patients receiving 400mg olaparib daily by oral 
administration (Dean et al, 2012), and 2µM paclitaxel (A2780pacR), the concentration at 
which A2780 cells became maximally stably resistant to paclitaxel. The additional ovarian 
cancer cell lines A1847 (Eva et al, 1982) and PE-01 (Langdon et al, 1988) and derivative cell 
lines were a generous gift from Professor Roland Wolf, Division of Cancer Research, 
University of Dundee. All cell lines were maintained in RPMI1640 medium containing 10% 
fetal bovine serum and 1% penicillin/streptomycin (± selection drugs), with additional 
supplementation of 1% sodium pyruvate and 1% L-glutamine for PE-01 lines, in 370C 
incubators, supplemented with 5% CO2. 
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siRNA-mediated ABCB1 gene knockdown 
 
A2780pacR and A2780olapR cells (2.5 x 105 cells per well) were seeded in six-well plates and 
incubated for 24 h before transient transfections using Lipofectamine RNAi MAX (Thermo 
Fisher Scientific, Loughborough, UK) with a final concentration of 25 nM ABCB1-specific 
siRNA (Dharmacon SMARTpool ON-TARGETplus; GE Healthcare Life Sciences, Little Chalfont, 
UK) or negative control (sterile water) in serum-free medium. The extent of ABCB1 




MTT chemosensitivity assays 
 
MTT assays (Mosmann, 1983) were used to compare the chemosensitivity of A2780, 
A2780olapR and A2780pacR cells and the additional cell lines described above to the 
chemotherapy drugs cisplatin, carboplatin, paclitaxel, doxorubicin, olaparib, AZD2461, 
veliparib and rucaparib and the ABCB1 inhibitors verapamil and elacridar. Each cell line was 
plated in a 96-well plate (5000 cells/well or 3000 cells/well for A1847 and PE-01 cell lines) 
and treated in triplicate with serial dilutions of each drug, at concentrations selected (where 
possible) to mimic typical peak plasma levels in ovarian cancer patients (range 0-200% [peak 
plasma]; cisplatin 0-25µM, carboplatin 0-85µM, paclitaxel 0-32µM, doxorubicin 0-5.5µM 
olaparib 0-50µM, AZD2461 0-20µM, veliparib 0-20µM and rucaparib 0-20µM)(Konecny et 
al, 2000). For ABCB1 inhibitor studies, cells were initially treated with a dose range from 0-
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100µM verapamil or elacridar to identify non-toxic inhibitor concentrations for use in future 
combination treatment studies, then subsequently combining 5µM and 10µM verapamil or 
elacridar with serial dilutions of paclitaxel or olaparib. Cells were drug treated for 72 hours, 
media removed and 100µl of a 0.5mg/ml MTT solution (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide in phenol red free DMEM) added and cells incubated at 37oC 
for 3 hours.  The resulting formazan crystals were solubilised in DMSO, quantitated 
spectrophotometrically at 570nm and the percentage of viable cells remaining following 
each drug treatment calculated (assigning a value of 100% to vehicle-treated cells). IC50 
values were calculated from log dose response curves using Prism 6 software (GraphPad 
Software Inc, La Jolla, USA).  
 
RNA and DNA extraction from cell lines 
 
Cells were grown to 80% confluency in 75cm2 flasks, harvested by trypsinisation, counted 
using a haemocytometer, and 1x107 cells used for RNA extraction using RNeasy mini kits 
(Qiagen, Manchester, UK), following the Manufacturer’s protocol for mammalian cells, with 
additional on column DNAse digestion (RNAse free DNAse kit, Qiagen). RNA yield and 
integrity were assessed from absorbance readings at 260nm and 280nm using a Nanodrop 
1000 spectrophotometer (Thermo Fisher Scientific, Loughborough, UK), according to the 
Manufacturer’s guidelines. Similarly, DNA was extracted from 3 x 106 cells using a DNeasy 
Blood and Tissue kit (Qiagen), following the Manufacturer’s protocol. DNA yield was 
assessed from absorbance readings at 260nm using a Nanodrop 1000 spectrophotometer, 
as described above.  
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Quantitative real-time PCR (qRT-PCR) analysis 
 
RNA was reverse transcribed into cDNA (200ng RNA per 50µl RT reaction) using Taqman 
Reverse Transcription Reagents kits (Life Technologies, Paisley, UK), according to the 
Manufacturer’s instructions, and the expression of ABCB1 (MDR1) (Taqman probe ID 
Hs00184500_m1), ABCC1 (MRP1) (Taqman probe ID Hs01561502_m1), PARP1 (Taqman 
probe ID Hs00242302_m1) and the loading control 18S ribosomal RNA (Taqman probe ID 
Hs99999901_s1) assessed by qRT-PCR analysis, as previously described (Smith et al, 2012), 
where 20µl individual reaction mixes (per well) contained 10µl Taqman Universal PCR 
Master Mix (Life Technologies), 1µl gene-specific Taqman probe, 1µl cDNA, and 8µl sterile 
water.  Each reaction was performed in triplicate and run on the Standard Real Time PCR 
program on a 7900 Taqman real-time PCR system (Life Technologies) using pre-defined 
thermal cycling conditions (500C for 2 minutes, 94.50C for 10 minutes, and then 40 cycles of 
970C for 30 seconds, 590C for 1 minute). Analysis of gene expression was performed using 
SDS 2.3 software (Life Technologies); optimal experimental baselines and thresholds were 
chosen for each gene, and gene expression in each cell line quantitated by cycle threshold 
(Ct) values. Relative expression values were determined by comparing the expression of 
each target gene with the invariant “loading control” 18S ribosomal RNA, as previously 
described (Smith et al, 2012). All samples were analysed in triplicate and gene expression 
calculated relative to 18S ribosomal RNA ± compound error ((SD target gene)2 + (SD 18S 
ribosomal RNA)2)½, where SD=standard deviation of the mean of triplicate replicates.   
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Copy number analysis 
ABCB1 (MDR1) copy number was assessed in A2780, A2780pacR and A2780olapR cells using 
a quantitative Taqman gene copy number assay (Taqman assay ID Hs04962504_cn), where 
ABCB1 copy number was compared to the copy number of the endogenous control gene 
RNAse P (Taqman Copy Number Reference Assay) by the comparative Ct method, and 
relative quantitation values obtained using CopyCaller Software (Life Technologies). As 
additional controls, ABCB1 and RNAse P copy numbers were assessed in peripheral blood 






Cells for protein extraction were harvested by trypsinisation as described above and protein 
extracts for ABCB1 analysis prepared in RIPA buffer (50mM Tris-HCl pH 8, 150mM NaCl, 
2mM EDTA, 0.1% SDS, 0.5% sodium deoxycholate, 50mM NaF, 1% Nonidet P-40) 
supplemented with EDTA-free protease inhibitor (Roche, Burgess Hill, UK) and for PARP1 
analysis in 2X SDS protein sample buffer (100mM Tris-HCl pH 6.8, 4% SDS, 0.04% 
Bromophenol blue, 20% Glycerol, 200mM DTT) followed by sonication of samples when 
required. Following 30 minutes incubation on ice with vortexing at regular intervals, lysed 
cells were centrifuged (14000rpm, 10 minutes, 4oC) to pellet cell debris, and protein 
concentrations of the resulting cell supernatants determined by Bradford Assay (ABCB1) or 
DC Protein Assay (PARP1) (BioRad, Hemel Hempstead, UK), relative to a standard curve 
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prepared from serial dilutions of bovine serum albumin (0-4mg/ml), with absorbance 
readings at 595nm or 750nm respectively.  
 
ABCB1 and PARP1 expression was analysed in protein extracts from each cell line by 
Western blotting, following SDS-PAGE. Each protein sample (15µg) was diluted in equal 
volumes of 2 x protein sample buffer (125mM Tris-HCl (pH 6.8), 4% SDS, 0.02% 
bromophenol blue, 0.2M DTT, 20% glycerol), denatured and separated by 12% SDS-PAGE 
gels in Tris-glycine buffer (25mM Tris pH 8.3, 250mM glycine, 0.1% SDS). Following 
electrophoresis, proteins were transferred to nitrocellulose membranes in Tris-glycine-
methanol buffer (48mM Tris pH8.3, 39mM glycine, 0.037% SDS, 20% methanol) and non-
specific antibody binding blocked by incubation for 2 hours in TBST (25mM Tris-HCl pH 7.6, 
150mM NaCl, 0.05% Tween-20) containing 5% milk powder. Membranes were then 
incubated overnight with a mouse monoclonal ABCB1 primary antibody (SC-55510, Santa 
Cruz Biotechnology, Heidelberg, Germany, diluted 1:1000), PARP1 (♯9542, Santa Cruz 
Biotechnology, diluted 1:1000) or a mouse monoclonal β-actin antibody (sc-47778, Santa 
Cruz Biotechnology, diluted 1:1000), washed in PBST (PBS supplemented with 0.05% Tween-
20) and incubated for 1 hour with a goat anti-mouse polyclonal secondary antibody (ABCB1; 
170-6516, BioRad, diluted 1:1000) or HRP-conjugated goat anti-rabbit polyclonal secondary 
antibody (PARP1; 170-6515; Biorad, diluted 1:3000).  Immunoblots were developed using an 




Immunohistochemical analysis  
A2780, A2780pacR or A2780olapR cells for immunohistochemical analysis were grown in 10 
cm2 dishes, harvested by scraping, centrifuged (1000rpm, 5min, RT) and re-suspended in 
50µl Normal Pooled Plasma (CCN-10, Alpha Laboratories, Eastleigh, UK).  Suspended cells 
were pelleted by adding 50µl Bovine Thrombin (BTUD293, Diagen Reagents Ltd, Thame, UK) 
and cell pellets immersed in 10% neutral buffered formalin prior to overnight processing on 
a Leica Peloris II processor using an 8hr xylene standard protocol. Processed cells were then 
embedded into paraffin wax.  Sections (4 µM) were cut onto Superfrost plus slides (Thermo 
Scientific)) and dried for 1 hr at 60oC.  Antigen retrieval and de-paraffinisation was 
performed using DAKO EnVision™ FLEX Target Retreval solution (high pH) buffer in a DAKO 
PT Link (Dako, Ely, UK). Immunostaining using DAKO EnVision™ FLEX system on a DAKO 
Autostainer Link48 was carried out according to manufacturer’s protocol.  Sections were 
incubated with 1/2000 dilution of ABCB1 primary antibody (SC-55510, Santa Cruz 
Biotechnology) for 30 mins. DAKO substrate working solution was used as a chromogenic 
agent for 2 x 5mins and sections were counterstained in EnVision™ FLEX hematoxylin.  
Negative controls were prepared by replacing the primary antibody with DAKO antibody 
diluent. 
 
P-glycoprotein activity assays 
Assessment of drug efflux activity in A2780, A2780pacR and A2780olapR cells and the 
influence of the ABCB1 inhibitor verapamil was performed using the Vybrant™ Multidrug 
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Resistance Assay Kit (Life Technologies) which estimates drug transporter activity by 
quantitative assessment of intracellular calcein accumulation. Cells were treated with the 
non-fluorescent prodrug calcein AM which crosses the cell membrane by passive diffusion 
and is cleaved in the cytoplasm by endogenous esterases, releasing fluorescent calcein. In 
ABCB1-expressing A2780pacR and A2780olapR cells, calcein AM is effluxed prior to esterase 
cleavage, resulting in reduced intracellular calcein fluorescence. A2780, A2780pacR and 
A2780olapR cells were plated in triplicate in cell culture medium in 96-well microplates (5 x 
105 cells/well) and incubated with 0.25µM calcein AM ± verapamil (0-25µM) for 15 minutes 
at 37oC.   Microplates were then centrifuged 3 times for 5 minutes at 200 x g, the cell 
supernatants removed and cells re-suspended in 200µl ice-cold cell medium. Intracellular 
calcein fluorescence was then measured using a fluorescence microplate reader, with 
absorption maximum=494nm and emission maximum=517nm. Relative calcein AM efflux in 
paired drug-sensitive and drug-resistant cell lines, and the influence of individual ABCB1 
inhibitors was assessed by plotting log10dose-response curves of calcein retention 
(fluorescence of inhibitor treated cells/fluorescence of untreated cells). 
 
Independent assessment of the potential of olaparib to act as either a substrate or inhibitor 
of P-glycoprotein was performed using the P-glycoprotein-Glo™ Assay System (Promega, 
Southampton, UK), according to the Manufacturer’s guidelines. The P-glycoprotein-Glo™ 
Assay System uses recombinant P-glycoprotein membranes to assess potential drug 
interactions based on ATP-dependent generation of a luminescent signal following 
activation of firefly luciferase, and therefore avoids potential confounding contributions 
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from additional drug transporters present in cell line analyses. Baseline P-glycoprotein 
membrane ATPase activity was first compared with the activity of membranes treated with 
the selective P-glycoprotein inhibitor sodium orthovanadate (final concentration 0.1mM) to 
quantify any minor non-P-glycoprotein-dependent ATPase activity in the recombinant 
membrane preparations. Membranes were then incubated with verapamil (final 
concentration 0.2µM; positive control) or with various concentrations of paclitaxel (8 and 
16µM), olaparib (12.5-50µ), veliparib (25 and 50µ), rucaparib (25 and 50µ), AZD2461 
(25 and 50µ), and ATPase activity assessed by quantitative assessment of luminescence 
(increased in the presence of P-glycoprotein substrates and decreased in the presence of 
inhibitors, relative to the activity of sodium orthovanadate-treated control samples).  
 
Whole-genome microarray mRNA analysis in A2780, A2780pacR and A2780olapR cells 
 
RNA was prepared from A2780, A2780pacR and A2780olapR cells and integrity assessed as 
described above. Each RNA sample was converted to biotinylated amplified cRNA using an 
Illumina TotalPrep RNA Amplification kit (Life Technologies) according to the manufacturer’s 
guidelines, and cRNA quality and concentration confirmed on an Agilent Bioanalyzer 2100 
(Agilent Technologies, Wokingham, UK). cRNA samples were hybridised in triplicate on 
Illumina Human HT-12 BeadChip Arrays (Illumina, Little Chesterford, UK) using standard 
protocols optimised by the Genetics Core, Wellcome Trust Clinical Research Facility, 





Gene expression data were analysed using Bioconductor 2.7 (http://bioconductor.org), 
running on R 2.12.1. Normalised probeset expression measures were calculated using log2 
transformation and quantile normalisation using the ‘Lumi’ package. To identify significant 
differences in gene expression in A2780, A2780pacR and A2780olapR cells, moderated 
Student’s t-tests were performed using empirical Bayes statistics in the ‘Limma’ package, 
and resulting P-values adjusted for multiple testing using the false discovery rate (FDR) 
Benjamini and Hochberg method (Smyth, 2004); probe sets with adjusted P-value FDR 








Creation of ovarian cancer cell lines resistant to paclitaxel and olaparib 
To investigate common mechanisms of paclitaxel and olaparib resistance we created A2780-
derived paclitaxel-resistant (A2780pacR) and olaparib-resistant (A2780olapR) cell lines as 
described in Materials and Methods, with drug concentrations selected to mimic typical 
treatment protocols in ovarian cancer patients. A2780pacR cells were more than 7-fold 
resistant to paclitaxel (7.49-fold increase in IC50(paclitaxel), (p<0.0001; Figure 1A), while 
A2780olapR cells were 36-fold resistant to olaparib (p<0.0001; Figure 1B). A2780pacR cells 
were significantly cross-resistant to olaparib (36.95-fold increase in IC50(olaparib), (p<0.0001; 
Figure 1C), although A2780olapR cells were not cross-resistant to paclitaxel (Figure 1D). 
Similarly, paclitaxel-resistant A1847TX1 and PE-01TX5 ovarian cancer cell lines were cross-
resistant to olaparib (Supplementary Figure 1), supporting our hypothesis that resistance 
may arise by a common mechanism. Neither A2780pacR nor A2780olapR cells were cross-
resistant to either cisplatin or carboplatin (data not shown).  
 
Olaparib and paclitaxel resistance leads to increased expression of ABCB1, the “multidrug 
resistance” drug efflux pump 
Increased ABCB1 expression has previously been reported in multiple paclitaxel-resistant 
cell lines and has been convincingly shown to influence paclitaxel chemosensitivity. We 
therefore used qRT-PCR analysis to confirm lack of ABCB1 mRNA expression in A2780 cells, 
but abundant expression in both A2780pacR, A2780olapR cells (Figure 2A) and 1847TX1 and 
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PEO1TX5 cells (Supplementary Figure 1). We then used quantitative gene copy number 
assays to investigate whether increased mRNA expression could be attributed to 
amplification of the ABCB1 gene. Consistent with more abundant ABCB1 mRNA expression, 
only A2780pacR cells were found to have amplified ABCB1, with 2 gene copies detected in 
DNA extracted from whole blood samples obtained from healthy volunteers, drug-sensitive 
A2780 cells and A2780olapR cells, but 4 gene copies detected in A2780pacR cells (Figure 2B). 
Changes in ABCB1 gene expression and copy number were reflected in ABCB1 protein 
expression, assessed both by Western blotting (Figure 2C) and immunohistochemical 
analysis (Figure 2D). Although increased P-glycoprotein expression was clearly present in 
both A2780pacR and A2780olapR cells, expression was highest in A2780pacR cells, 
consistent with increased ABCB1 copy number. As increased expression of the alternative 
multidrug resistance protein ABCC1 (MRP1) has also been associated with paclitaxel 
resistance in various cancer cell lines (Allen et al, 2000) we additionally used qRT-PCR 
analysis to compare ABCC1 levels in A2780, A2780pacR and A2780olapR cells, but found no 
differences in expression (data not shown). To extend our analysis of differential ABC 
transporter expression, we use whole genome microarray analysis (Agilent HT-12 arrays) to 
perform an unbiased comparison of gene expression in A2780, A2780pacR and A2780olapR 
cells, as described in Materials and Methods. ABCB1 was the only drug transporter with 
significantly increased expression in resistant cells (Supplementary Table 1); ABCB1 probe 
sets were the first and second most abundantly induced probe sets from 12, 590 probe sets 
significantly altered in A2780pacR cells, and the 4th and 6th most abundantly induced probe 
sets from 11, 182 probe sets significantly altered in A2780olapR cells. It was also interesting 
to note that the expression of several ABC transporters (A2780pacR: ABCA1, ABCA2, ABCB7, 
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ABCB9, ABCC4, ABCC5, ABCC6, ABCC10 and ABCG4; A2780olapR: ABCB6, ABCB9, ABCC4, 
ABCD3, ABCE1, ABCF2 and ABCG4) was significantly decreased in resistant cells.  
 
Paclitaxel and olaparib resistance can be reversed by the ABCB1 inhibitors verapamil and 
elacridar 
To further test our hypothesis that resistance to both paclitaxel and olaparib is influenced 
by increased ABCB1-mediated drug efflux, we treated A2780pacR and A2780olapR cells with 
the ABCB1 inhibitors verapamil and elacridar. Verapamil, a calcium channel-blocker and 
anti-arrythmic drug, is a competitive ABCB1 inhibitor (Cornwell et al, 1987; Safa, 1988), 
while elacridar does not directly compete with ABCB1 substrates for active site binding but 
regulates protein function through allosteric inhibition (Hyafil et al, 1993). Initial MTT assays 
were performed with both inhibitors in A2780, A2780pacR and A2780olapR cells to identify 
non-toxic doses (5µM and 10µM) for use in subsequent combination treatment 
experiments (data not shown). Dose-dependent increases in chemosensitivity were 
subsequently observed following combination treatment, with a complete reversal of 
paclitaxel resistance in both A2780pacR cells (Figure 3A) and A2780olapR cells (Figure 3B) 
treated with paclitaxel, following combination treatment with 10µM verapamil. Verapamil 
was a less efficient competitive inhibitor in olaparib-resistant cells, although a >80% re-
sensitisation to olaparib was observed in A2780olapR cells (Figure 3C). Consistent with these 
findings, combination treatment with the more potent ABCB1 inhibitor elacridar resulted in 
complete reversal of both paclitaxel and olaparib resistance (Figures 3D-F). Further, re-
sensitisation to paclitaxel and olaparib was additionally observed in A2780pacR and 
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A2780olapR cells where ABCB1 expression was disrupted following transient siRNA 
knockdown (Supplementary Figure 2). As ABCB1 expression is approximately 10-fold higher 
in A2780pacR than in A2780olapR cells (Panels A and B) as a consequence of a gene 
duplication event, it is not surprising that siRNA disruption was less effective in A2780pacR 
than in A2780olapR cells.  
 
Paclitaxel and olaparib are actively effluxed from drug-resistant A2780pacR and 
A2780olapR cells 
To investigate whether paclitaxel and olaparib are actively effluxed from drug-resistant cells, 
we compared the ability of A2780, A2780pacR and A2780olapR cells to efflux the model 
substrate CalceinAM. CalceinAM is a prodrug which is cleaved to fluorescent calcein by 
intracellular esterases; ATP-dependent CalceinAM efflux is increased in the presence of 
ABCB1, thus limiting esterase cleavage and fluorescent calcein production. Consistent with 
increased ABCB1 activity, calcein fluorescence was significantly reduced in A2780pacR and 
A2780olapR cells (6.18-fold p=0.005 and 4.49-fold, p=0.03; Figures 4A). We then assessed 
intracellular calcein fluorescence in the presence of increasing concentrations of verapamil. 
Verapamil treatment did not influence CalceinAM efflux in drug-sensitive A2780 cells which 
do not express ABCB1, but caused a dose-dependent decrease in Calcein AM efflux 
(assessed by increased intracellular calcein fluorescence) in both A2780pacR and 
A2780olapR cells (Figure 4B).  
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To further confirm that both paclitaxel and olaparib are P-glycoprotein substrates, we used 
luminescent P-glycoprotein-Glo™ assays as described in Materials and Methods, where the 
influence of paclitaxel and olaparib on recombinant P-glycoprotein activity was evaluated in 
cell membrane fractions.  Similar to verapamil (positive control), the addition of either 
paclitaxel or olaparib lead to a dose-dependent increase in ATPase activity (indirectly 
assessed by relative luciferase activity), confirming a direct protein/substrate interaction 
(Figure 4C). 
 
Paclitaxel and olaparib-resistant cells are cross-resistant to doxorubicin and rucaparib, but 
not to the alternative PARP inhibitors AZD2461 and veliparib 
Liposomal doxorubicin is commonly prescribed as second-line chemotherapy to ovarian 
cancer patients with relapsed platinum/taxane resistant disease. The first description of 
ABCB1-mediated drug resistance in various cancer cell lines reported both increased ABCB1 
mRNA expression and copy number in adriamycin (also known as doxorubicin)-resistant 
A2780 cells (Shen et al, 1986), while numerous subsequent studies have confirmed that 
doxorubicin is a P-glycoprotein substrate. We therefore predicted that paclitaxel and 
olaparib-resistant cells may also be cross-resistant to doxorubicin – as expected, both 
A2780pacR (Figure 5A) and, to a lesser extent, A2780olapR (Figure 5B) cells were 
significantly more resistant to doxorubicin than A2780 cells. Similar paclitaxel/doxorubicin 
cross-resistance was observed in A1847TX1 and PEO1TX5 cells (Supplementary Figure 1). 
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To investigate whether ABCB1-mediated drug resistance could be avoided by prescription of 
an alternative PARP inhibitor, we next investigated whether A2780pacR (Figure 5C) or 
A2780olapR (Figure 5D) cells were cross-resistant to AZD2461, a novel PARP inhibitor with 
low affinity for P-glycoprotein (Jaspers et al, 2013). No cross-resistance was observed, 
confirming that AZD2461 is a poor P-glycoprotein substrate and suggesting that the 
prescription of an alternative PARP inhibitor may avoid the treatment-limiting complication 
of ABCB1-induced drug resistance. Similarly, A2780pacR and A2780olapR cells were not 
cross-resistant to the PARP inhibitor veliparib (Figure 5E and 5F), but were significantly 
cross-resistant to rucaparib (Figure 5G and 5H). To further confirm that doxorubicin and 
rucaparib are P-glycoprotein substrates, we repeated the P-glycoprotein-Glo™ assays 
described above and demonstrated dose-dependent increases in ATPase activity following 
incubation with doxorubicin and rucparib, but not with any of the other PARP inhibitors 
tested  (Figure 6).  We additionally confirmed that altered chemosensitivity did not result 
from altered PARP1 expression in A2780pacR or A2780olapR cells, assessed both by qRT-
PCR analysis and Western blotting (Supplementary Figure 3) and in our whole genome 
microarray analysis, described above, where we did not observe significant differences in 







The development of chemotherapy-induced drug resistance is a major treatment-limiting 
complication in the treatment of ovarian cancer (Vaughan et al, 2011).  Many drug 
resistance mechanisms involve adaptation of drug metabolism or drug disposition pathways 
in resistant cancer cells, which normally function to protect healthy cells from exposure to 
toxic chemicals. One of the most well characterised examples of cellular adaptation is 
increased activity of the membrane-bound ATP-dependent “multidrug resistance” drug 
efflux pump P-glycoprotein, encoded by the ABCB1 (MDR1) gene (Kathawala et al, 2015). 
Increased P-glycoprotein activity, often as a result of a chemotherapy-induced gene 
amplification event, has been associated with the development of drug resistance in a 
variety of human solid tumours and haematological cancers (Thomas & Coley, 2003). 
ABCB1-mediated drug resistance mechanisms are of particular relevance to ovarian cancer 
as paclitaxel, used routinely in combination with carboplatin in first-line chemotherapy 
protocols, is one of the most well characterised P-glycoprotein substrates which is efficiently 
effluxed from drug resistant cells (Sikic et al, 1997).  
 
Our data confirms many previous reports of an ABCB1-mediated adaptive resistance 
mechanism in paclitaxel-resistant ovarian cancer cell lines and xenograft models (e.g. 
(Ahmed et al, 2007; Boesch et al, 2015; Ingemarsdotter et al, 2015; Syed et al, 2011), and 
describes a common mechanism of resistance to PARP inhibitors, including olaparib and 
rucaparib. ABCB1-mediated resistance to PARP inhibitors is a novel finding in ovarian cancer, 
 24 
and is of particular clinical relevance as olaparib and related drugs are currently being 
evaluated in multiple clinical trials as second-line or maintenance chemotherapy options, 
often in paclitaxel pre-treated patients. It is therefore particularly important that our data 
suggests that some (e.g. rucaparib) but not all (e.g. veliparib, AZD2461) alternative PARP 
inhibitors are P-glycoprotein substrates and are actively effluxed from paclitaxel-resistant 
cells – optimal PARP inhibitor choice, particularly in paclitaxel-resistant patients, may 
therefore be an important determinant of clinical response. Consistent with this hypothesis, 
comparison of olaparib with the novel PARP inhibitor AZD2461 in a mouse mammary 
tumour model, showed greater efficacy following administration of AZD2461, which we and 
others have shown is a poor P-glycoprotein substrate (Jaspers et al, 2013), while recent 
advances in PARP inhibitor development have prioritised drug candidates, for example, 
novel 7-azaindole-1-carboxamide derivatives, which are not P-glycoprotein substrates 
(Cincinelli et al, 2014).  Although our A2780olapR cells were not cross-resistant to paclitaxel, 
we believe this to be an ABCB1 threshold effect, and highlight the potential for olaparib and 
rucaparib to additionally induce P-glycoprotein-mediated resistance, particularly if 
prescribed for an extended period, for example as long-term maintenance treatment.  It is 
also important to note that doxorubicin, frequently prescribed to ovarian cancer patients in 
a liposomal formulation as second-line chemotherapy for recurrent disease is also a well-
known P-glycoprotein substrate (Shen et al, 1986), which is also actively effluxed from 
paclitaxel-resistant cells.  
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The first suggestion that clinical response to olaparib may be compromised by altered drug 
efflux was proposed by Rottenberg et al in 2008, describing increased murine Abcb1a/b 
expression in a drug-resistant mouse mammary tumour model, where resistance was 
reversible with the P-glycoprotein inhibitor tariquidar (Rottenberg et al, 2008). 
Subsequently, increased Abcb1b expression has been reported in a murine BRCA2-
dependent breast cancer model following exposure to olaparib, docetaxel or doxorubicin 
(Jaspers et al, 2015), while rucaparib has recently been reported to be a substrate for both 
ABCB1 and ABCG2 (Durmus et al, 2015). Intriguingly, experiments in mouse embryonic 
fibroblasts have suggested that doxorubicin resistance is caused by increased P-glycoprotein 
expression and activity in PARP1 null cells (Wesierska-Gadek, 2005; Wurzer et al, 2000), 
while Dumitriu et al demonstrated that PARP inhibitors increase P-glycoprotein activity in 
both mouse and human lymphocytes (Dumitriu et al, 2004). If a similar mechanism is 
present in ovarian cancer cells, sequential paclitaxel and PARP inhibitor treatment could 
therefore further potentiate the development of ABCB1-mediated drug resistance.  
 
Our data suggests that both paclitaxel and olaparib-induced resistance is reversible 
following combination treatment with a P-glycoprotein inhibitor. Early clinical trials of P-
glycoprotein inhibitors have been disappointing, however, due in part to verapamil 
cardiotoxicity (Ozols et al, 1987), although a hyaluronic acid based CD44-targeted MDR1 
siRNA was recently shown to successfully reverse paclitaxel resistance in SKOV 3 cells (Yang 
et al, 2015) and a more recent clinical trial of tariquidar in docetaxel-treated patients 
demonstrated P-glycoprotein inhibition in vivo (Kelly et al, 2011). A variety of novel P-
 26 
glycoprotein inhibitors are currently in development, including CB-PIC (Yun et al, 2015) and 
the bisbenzylisoquinoline CBT-1, a novel inhibitor which inhibits P-glycoprotein without 
influencing paclitaxel pharmacokinetics (Kelly et al, 2012).  
 
In addition to the obvious potential to target P-glycoprotein therapeutically, assessment of 
ABCB1 copy number or P-glycoprotein mRNA or protein expression may also have clinical 
utility as drug resistance biomarkers in cancer patients. Consistent with our own data, 
ABCB1 copy number changes or increased P-glycoprotein expression (without associated 
copy number changes) have been widely reported in paclitaxel and docetaxel-resistant 
ovarian cancer cell lines e.g. (Wang et al, 2006) and in recurrent ovarian cancers (Zajchowski 
et al, 2012), suggesting that clinical assessment of changes in ABCB1 expression or activity 
may have greatest prognostic potential as patients progress through chemotherapy. It is 
also interesting to note, however, that analysis of public domain ovarian cancer datasets 
from The Cancer Genome Atlas (TCGA) identifies a subset (approximately 2%) of 
chemotherapy-naive ovarian cancer patients with ABCB1 gene amplifications and a similar 
number of patients with high basal ABCB1 mRNA expression, suggesting that these patients 
may be inherently resistant to paclitaxel, doxorubicin and selected PARP inhibitors. 
Consistent with this finding, amplification of regions of chromosome 7q21 spanning the 
ABCB1 gene locus have frequently been described in ovarian cancer (Micci et al, 2014; 
Partheen et al, 2004; Tapper et al, 1997). High basal ABCB1 expression has also been 
described in subsets of inherently resistant ovarian cancers (Arao et al, 1994; Holzmayer et 
al, 1992), and in a series of chemo-naïve ovarian tumours where P-glycoprotein expression 
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was inversely correlated with survival (Materna et al, 2004). Although the majority of 
previous studies are cell line based, it is interesting to note that ABCB1 is one of several 
genes with increased expression in chemo-resistant breast cancers (Krech et al, 2012) and in 
paclitaxel-resistant ovarian cancers (Penson et al, 2004), while a recent whole-genome 
sequence based comparison of drug-sensitive and drug-resistant ovarian cancers described 
a novel gene promoter fusion in which ABCB1 is fused with SLC25A40 in chemotherapy 
resistant cancers, resulting in increased P-glycoprotein expression (Patch et al, 2015).  
Unfortunately, our ability to evaluate ABCB1 expression in ovarian cancer patients before 
and following PARPi-based chemotherapy is limited by the current lack of clinical material 
outwith the clinical trial setting.  
 
Should our cell line data be confirmed in vivo, we further highlight the potential for 
inherited differences in ABCB1 activity to modify clinical response. Although not all 
published studies are consistent (e.g. (Johnatty et al, 2013; Marsh et al, 2007), inheritance 
of the ABCB1 G2677T/A allele has been shown to influence paclitaxel clearance (Fransson et 
al, 2011; Green et al, 2006), the C2005T polymorphism to influence substrate specificity (Liu 
et al, 2010) and various ABCB1 alleles to influence survival in both breast (Chang et al, 2009) 
and ovarian (Johnatty et al, 2013; Kim et al, 2009) paclitaxel-treated patient cohorts.  It is 
therefore particularly important to note that only one third of ovarian cancer patients 
responded to second-line olaparib treatment in recent clinical trials (Audeh et al, 2010), 
when majority of enrolled patients had failed to respond to previous chemotherapy and 
almost all patients had been pre-treated with paclitaxel (median of 3 previous 
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chemotherapy regimens) – it is therefore tempting to speculate than non-responders had 
altered ABCB1 expression, and we encourage testing of this hypothesis in clinical trial 
cohorts.  
 
Our experimental models, combining novel drug-resistant cell lines with functional drug 
transport assays provide a useful system for the evaluation of additional PARP inhibitors, 
and more detailed analysis of potential drug/drug interactions - studies with additional 
PARP inhibitors are ongoing in our laboratory. We were particularly interested to learn of a 
recent report describing synergistic effects of olaparib and cediranib (Liu et al, 2014), 
particularly as cediranib was previously shown to be a potent P-glycoprotein inhibitor (Tao 
et al, 2009), and hypothesised that clinical response may result from cediranib-induced 
inhibition of ABCB1-mediated olaparib efflux.  Experiments in our drug-resistant cell lines 
did not confirm this hypothesis (data not shown), however, consistent with a recent report 
suggesting that there may be an immunological basis for response to combination 
treatment (Lee et al, 2015).  
 
In summary, our data describes a novel mechanism of PARP inhibitor resistance in ovarian 
cancer and highlights the importance of evaluating ABCB1 expression in ongoing and future 
clinical trials. If our hypotheses are confirmed in extended clinical series, our data strongly 
suggests that optimal choice of PARP inhibitor may limit the progression of drug resistant 
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disease, and further suggests that routine prescription of first-line paclitaxel may 
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Figure 1: Cross-resistance of paclitaxel and olaparib-resistant ovarian cancer cell lines. 
Novel ovarian cancer A2780-derived paclitaxel (A2780pacR) and olaparib (A2780olapR) 
resistant cell lines were created as described in Materials and Methods. MTT 
chemosensitivity assays were used to compare cell viability following exposure to serial 
dilutions of paclitaxel (panels A and D) and olaparib (panels B and C) in A2780 and 
A2780pacR (panels A and C) and A2780olapR (panels B and D) cells. Chemosensitivity values 
obtained from triplicate replicate experiments, expressed as IC50 values, are summarised in 
Panel E. 
 
Figure 2: ABCB1 (P-glycoprotein) expression is increased in A2780pacR and A2780olapR cells. 
ABCB1 mRNA expression (panel A), copy number (panel B), and P-glycoprotein expression 
(panels C and D) was compared in A2780, A2780pacR and A2780olapR cells by qRT-PCR 
analysis, Taqman-based copy number analysis, Western blotting and immunohistochemical 





Figure 3: Paclitaxel and olaparib resistance are reversible following combination treatment 
with the P-glycoprotein inhibitors verapamil and elacridar.  
MTT chemosensitivity assays were used as described in Materials and Methods to compare 
cell viability following exposure to serial dilutions of paclitaxel and olaparib in A2780, 
A2780pacR and A2780olapR cells in the presence and absence of combination treatments 
(5µM and 10µM) with the P-glycoprotein inhibitors verapamil (Panels A-C) and elacridar 
(panels D-F). 
 
Figure 4: P-glycoprotein mediated drug efflux is altered in paclitaxel and olaparib resistant 
cells. 
(A) Vybrant™ Multidrug Resistance Assays were used, as described in Materials and 
Methods, to compare P-glycoprotein dependent efflux of the model substrate Calcein-AM in 
untreated A2780, A2780pacR and A2780olapR cells and (B) in the presence of 0-25µM 
verapamil. Results were confirmed (Panel C) using the P-glycoprotein-Glo™ Assay System, as 
described in Materials and Methods, to demonstrate dose-dependent increases in 
luminescence following the incubation of paclitaxel or olaparib with P-glycoprotein 





Figure 5: Paclitaxel and olaparib resistant cells are cross-resistant to doxorubicin and 
rucaparib, but not to AZD2461 or veliparib.  
MTT chemosensitivity assays were used as described in Materials and Methods to compare 
cell viability in A2780, A2780pacR and A2780olapR cells following exposure to serial 
dilutions of doxorubicin (Panels A and B), AZD2461 (Panels C and D), veliparib (Panels E and 
F) and rucaparib (Panels G and H). Chemosensitivity values obtained from triplicate replicate 
experiments, expressed as IC50 values, are summarised in Panel I. 
 
Figure 6: The PARP inhibitors olaparib and rucaparib are P-glycoprotein substrates, while the 
alternative PARP inhibitors AZD2461 and veliparib are not actively effluxed.  
The P-glycoprotein-Glo™ Assay System was used, as described in Materials and Methods, to 
investigate whether dose-dependent increases in luminescence were observed following 
the incubation of verapamil (positive control), olaparib, veliparib, rucaparib or AZD2461 
with P-glycoprotein containing membranes.  
 
Supplementary Figure 1 
qRT-PCR analysis was used as described in Materials and Methods to confirm increased 
ABCB1 expression in paclitaxel-resistant (A) 1847TX1 and (B) PEO1TX5 cells, relative to drug-
sensitive parental cells. MTT chemosensitivity assays were used as described in Materials 
and Methods to compare cell viability following exposure to serial dilutions of paclitaxel 
 43 
(panels C and F), olaparib (panels D and G) and doxorubicin (panels E and H) in matched 
drug-sensitive and drug-resistant cell line pairs. 
 
Supplementary Figure 2 
ABCB1 expression was disrupted following siRNA transfection in (A) A2780pacR and (B) 
A2780olapR cells, as described in Materials and Methods (control cells were transfected 
with sterile water).  Gene knockdown is illustrated 24 hours following transfection, although 
was maintained from 24 -72 hours post transfection. MTT chemosensitivity assays were 
used as described in Materials and Methods to compare the viability of drug-sensitive, drug-
resistant and siRNA knockdown cells following exposure to serial dilutions of (C) paclitaxel 
and (D) olaparib.  
 
Supplementary Figure 3 
(A) qRT-PCR analysis and (B) Western blotting was used as described in Materials and 
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GENE ALIAS FOLD CHANGE p-value FOLD CHANGE p-value
probe set 1 (adjusted) probe set 2 (adjusted)
Fold increase in A2780pacR cells (relative to A2780)
ABCA1 ABC1, CERP -2.29 3.55E-10
ABCA2 ABC2 -25.49 1.17E-03
ABCA3 ABC3 0.10 1.26E-05
ABCA7 ABCX -0.65 4.66E-11
ABCA11P none 0.05 8.54E-04
ABCB1 MDR1, PGY1 35.94 2.16E-22 45.52 1.53E-22
ABCB7 ABC7 -3.38 1.15E-05
ABCB9 none -2.09 1.11E-09 -5.13 3.55E-06
ABCB10 MABC2, MTABC2 1.13 2.72E-11
ABCC3 MRP3, CMOAT2 0.02 1.26E-02
ABCC4 MRP4, MOATB -28.19 1.36E-03
ABCC5 MRP5, MOATC -17.33 8.17E-04 0.02 1.69E-03
ABCC6 MRP6, ARA -64.47 1.58E-02 0.02 3.97E-03
ABCC8 SUR, SUR1 0.05 3.96E-04
ABCC10 MRP7 -15.33 3.10E-05
ABCD3 PXMP1, PMP70 0.14 2.14E-06
ABCE1 RNS4I 0.08 3.94E-03 0.13 1.22E-05
ABCF1 ABC50 0.03 4.30E-02
ABCF2 HUSSY18 0.11 1.65E-06
ABCF3 none 0.02 1.11E-02
ABCG4 WHITE2 -3.01 4.92E-10
Fold increase in A2780olapR cells (relative to A2780)
ABCA2 ABC2 0.13 2.03E-06
ABCA3 ABC3 0.04 2.87E-03
ABCA17P none 0.02 8.02E-03
ABCB1 MDR1, PGY1 15.38 3.18E-20 17.14 3.18E-20
ABCB6 MTABC3 -11.14 4.09E-04
ABCB7 ABC7 0.09 5.97E-03
ABCB9 none -39.60 4.16E-02 0.04 2.16E-03
ABCB10 MABC2, MTABC2 0.20 2.80E-06
ABCC3 MRP3, CMOAT2 0.34 6.65E-10
ABCC4 MRP4, MOATB -15.59 8.03E-04 -18.70 2.33E-04
ABCC5 MRP5, MOATC 0.14 8.84E-08
ABCC6 MRP6, ARA 0.03 3.97E-03
ABCC8 SUR, SUR1 0.12 3.58E-06
ABCD1 ALDP 0.09 1.09E-06
ABCD3 PXMP1, PMP70 -14.31 1.56E-04
ABCE1 RNS4I -12.20 4.89E-03 -14.27 4.47E-04
ABCF1 ABC50 -1.49 8.03E-10 -1.02 1.74E-10
ABCF2 HUSSY18 -3.24 3.46E-09 -48.85 3.77E-02
ABCF3 none 0.04 9.38E-04
ABCG1 ABC8, WHITE 0.11 1.64E-05
ABCG4 WHITE2 -7.03 1.82E-07
ABCB1 is the first and second most abundantly induced probe set (from 12,590 probe sets 
significantly altered) in A2780pacR cells, and the 4th and 6th most abundantly induced probe 
set (from 11,182 probe sets significantly altered) in A2780olapR cells.
Genes with fold changes less than a pre-defined threshold of 2 are greyed out, as they are not 
considered to be functionally significant.
